CytoSorbents Corporation (CTSO)

[cars100cars]

Wondering if traders realize there is no US political risk in CTSO stock and if the sell off with US healthcare is in error? Sure, US biotech and healthcare are getting hit due to current political risks here. But there's no connection to CTSO. While it is a New Jersey company, all CTSO sales come from 42 foreign countries. CytoSorb is not sold in the US yet. Paulness, thanks for your prediction of $3 million in revenues for Q316. We'll know next week. I'm guessing $2.8 million. Anything over $3 million would be a blockbuster, considered total sales were about $4 million last year. Looks like CTSO is on track to easily double 2015 revenues. The acceleration in growth is just beginning with partners like Terumo and Fresenius still in the very early stages of their marketing programs for the CytoSorb brand. Biocon (India) is a wild card, as is Russia and the Middle East. Penetration is just beginning in South America, too. Maybe Canada is next? Also, interesting note in the release this week about two additional markets coming on board -- the story mentioned the strong gross margins (60%+) continue to be in place. This could be a real cash cow. The case history report also indicated CytoSorb is becoming the Standard of Care for sepsis cases. All the parts and pieces continue to fit together -- all good signs for continued revenue growth. US politics won't affect any of CTSO's fundamental growth drivers. Fear alone can't hold CTSO down too long.